|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:AbbVie
|
|
gptkbp:acquisitionYear
|
2023
|
|
gptkbp:CEO
|
Mark Enyedy
|
|
gptkbp:collaboratedWith
|
gptkb:Takeda
gptkb:Eli_Lilly_and_Company
gptkb:Sanofi
gptkb:Amgen
gptkb:Novartis
gptkb:Roche
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:developedBy
|
targeted cancer therapeutics
|
|
gptkbp:focus
|
antibody-drug conjugates
|
|
gptkbp:focusesOn
|
gptkb:cancer
hematologic malignancies
|
|
gptkbp:founded
|
1981
|
|
gptkbp:founder
|
Wayne A. Marasco
|
|
gptkbp:headquarters_location
|
gptkb:Waltham,_Massachusetts,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
mirvetuximab soravtansine
|
|
gptkbp:numberOfEmployees
|
~300
|
|
gptkbp:platform
|
antibody-drug conjugate technology
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:specializesIn
|
oncology
|
|
gptkbp:stockSymbol
|
IMGN
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.immunogen.com/
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Route_128_corridor
gptkb:Baker_Bros._Advisors
gptkb:WuXi_Biologics
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ImmunoGen
|